Dan.Hno
DAN.HNO operates in the Pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
Business. DANA Inc (NYSE: DAN) is an automobile manufacturer operating within the Automobiles & Auto Parts industry. The company generates revenue through the sale of products. Headquarters and specific operating segment details are not provided in the available data. DANA Inc is primarily listed on the New York Stock Exchange under the ticker symbol DAN.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
DANA Inc (NYSE: DAN) is an automobile manufacturer operating within the Automobiles & Auto Parts industry. The company generates revenue through the sale of products. Headquarters and specific operating segment details are not provided in the available data. DANA Inc is primarily listed on the New York Stock Exchange under the ticker symbol DAN.
DAN.HNO's capital structure is characterized by a debt-to-equity ratio of 0.8, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.27, suggesting it can cover its short-term obligations but with limited buffer. Free cash flow is negative at -116,911,444,050, which may signal reinvestment in the business or operational inefficiencies.
Profitability metrics show a return on equity of 10.08% and a return on assets of 3.93%. These figures are to be compared against the industry's preferred metrics, which typically emphasize high ROE and ROA for pharmaceutical firms. The company's operating income margin is 16.71% (108,084,255,630 / 647,285,780,420), which is a strong indicator of operational efficiency. However, the net income margin of 13.25% (85,749,552,730 / 647,285,780,420) suggests that the company is managing to convert a significant portion of its revenue into profit.
The company's revenue is not segmented by geographic regions or product lines in the provided data, making it difficult to assess the geographic exposure or the contribution of different segments to the overall revenue. However, the absence of cash and equivalents (0.0) and the negative free cash flow indicate that the company may be investing heavily in its operations or facing liquidity constraints.
The growth trajectory of DAN.HNO is not explicitly provided in the data, but the negative free cash flow and the capital expenditure of -219,161,497,270 suggest that the company is investing in its long-term growth. The operating cash flow of 55,120,882,900 indicates that the company is generating positive cash from its operations, which is a positive sign for its ability to fund its operations and investments.
The risk assessment for DAN.HNO includes a medium liquidity risk, which is due to the company's negative net cash position after subtracting total debt. The dilution risk is assessed as low, which implies that the company is not expected to issue additional shares that could dilute existing shareholders' equity in the near term. The capital structure and the company's financial leverage are key factors in the risk profile.
Recent events or filings that could impact the company's financial performance are not detailed in the provided data. However, the company's financial snapshot and valuation metrics provide a snapshot of its current financial health and operational performance.
- DAN.HNO has a moderate debt-to-equity ratio of 0.8, indicating a balanced capital structure.
- The company's return on equity of 10.08% is a strong indicator of profitability.
- The negative free cash flow of -116,911,444,050 suggests that the company is investing in its operations or facing liquidity constraints.
- The operating cash flow of 55,120,882,900 indicates that the company is generating positive cash from its operations.
- The company's liquidity position is assessed as medium, with a current ratio of 1.27.
- **margin_outlook_rationale**: The company's operating margin is strong at 16.71%, which is a positive indicator for future profitability.
- **rd_outlook_rationale**: The company's capital expenditure of -219,161,497,270 suggests ongoing investment in research and development.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- VP & Chief Accounting Officer · Restricted Stock Units → Common Stock, par value $0.01Disposed 6 186exercise · 2026-07-23
- VP & Chief Accounting Officer · Dividend Equivalent Rights → Common Stock, par value $0.01Disposed 101exercise · 2026-07-23
- SVP & Pres Comm Veh Drive · Restricted Stock Units → Common Stock, par value $0.01Disposed 19 400exercise · 2026-07-22
- SVP & Pres Comm Veh Drive · Dividend Equivalent Rights → Common Stock, par value $0.01Disposed 958exercise · 2026-07-22
- Director, Chairman & CEO · Restricted Stock Units → Common Stock, par value $0.01Acquired 190 694grant · 2026-07-01
- Director, Chairman & CEO · Restricted Stock Units → Common Stock, par value $0.01Acquired 31 155grant · 2026-06-29
- Director · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 18grant · 2026-05-29
- Pres, Light Veh Drive Systems · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 297grant · 2026-05-29
- Director · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 18grant · 2026-05-29
- VP & Chief Accounting Officer · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 101grant · 2026-05-29
- SVP & Chief Financial Officer · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 403grant · 2026-05-29
- Director · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 18grant · 2026-05-29
- Director · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 18grant · 2026-05-29
- Director, Chairman & CEO · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 625grant · 2026-05-29
- Director · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 18grant · 2026-05-29
- SVP, General Counsel and Secty · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 212grant · 2026-05-29
- Director · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 18grant · 2026-05-29
- SVP & Pres Comm Veh Drive · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 304grant · 2026-05-29
- Director, Chairman & CEO · Restricted Stock Units → Common Stock, par value $0.01Acquired 22 808grant · 2026-05-28
- Director · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 21grant · 2026-03-20
- Director · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 21grant · 2026-03-20
- SVP & Pres Comm Veh Drive · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 342grant · 2026-03-20
- Director · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 21grant · 2026-03-20
- Director · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 21grant · 2026-03-20
- SVP, General Counsel and Secty · Dividend Equivalent Rights → Common Stock, par value $0.01Acquired 239grant · 2026-03-20
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- DAN.HNO Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,11 %$207M
- Investment Managers · as of 2026-03-310,06 %$281M
- Institutional Investor · as of 2022-09-300,04 %$0M
- Funds · as of 2026-03-310,02 %$117M
- Investment Managers · as of 2026-03-310,01 %$19M
- Investment Managers · as of 2026-03-310,01 %$22M
- Investment Managers · as of 2026-03-310,01 %$50M
- Investment Managers · as of 2026-03-310,01 %$49M
- Investment Managers · as of 2024-06-300,01 %$285M
- Investment Managers · as of 2026-03-310,01 %$104M
- Institutional Investor · as of 2026-03-310,01 %$33M
- Investment Managers · as of 2026-03-310,01 %$45M
- Investment Managers · as of 2026-03-310,01 %$164M
- Investment Managers · as of 2026-03-310,01 %$8M
- Investment Managers · as of 2025-12-310,00 %$340M
- Investment Managers · as of 2026-03-310,00 %$32M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$45M
- Institutional Investor · as of 2026-03-310,00 %$9M
- Brokerage Firms · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2024-12-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$3M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$3M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
- VP & Chief Accounting Officer · Common Stock, par value $0.01Other 101 · 2026-07-23
- VP & Chief Accounting Officer · Common Stock, par value $0.01Other 1 799 @ $28,04$50K · 2026-07-23
- VP & Chief Accounting Officer · Common Stock, par value $0.01Other 6 186 · 2026-07-23
- SVP & Pres Comm Veh Drive · Common Stock, par value $0.01Other 958 · 2026-07-22
- SVP & Pres Comm Veh Drive · Common Stock, par value $0.01Other 8 877 @ $27,43$243K · 2026-07-22
- SVP & Pres Comm Veh Drive · Common Stock, par value $0.01Other 19 400 · 2026-07-22
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Operating income (YoY) (2025-12-31 vs 2024-12-31): 179.0%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -37.0%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -6.2%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 264.1%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -3.0%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 13.8%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 264.1%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 249.1%Derived (calculated)
- Net margin (FY 2025-12-31): 1.1%Derived (calculated)
- Return on equity (FY 2025-12-31): 10.1%Derived (calculated)
- Return on assets (FY 2025-12-31): 1.1%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.17xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 8.22xDerived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 17.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 4.3%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -42.9%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -5.1%Derived (calculated)
- Total liabilities (annual): USD 6.91BSEC XBRL filing
- Current liabilities (annual): USD 3.31BSEC XBRL filing
- Current assets (annual): USD 3.87BSEC XBRL filing
- Cash & equivalents (annual): USD 469MSEC XBRL filing
- Total assets (annual): USD 7.81BSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 1SEC XBRL filing
- Net income (annual): USD 85MSEC XBRL filing